FDAsafety guidance66% confidence
FDA AP — ILUMYA (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761067. Sponsor: SUN PHARMA GLOBAL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: TILDRAKIZUMAB-ASMN.
Supporting Context
- Therapeutic area
- Immunology · IL-23
- Sub-indication
- Ild
Related signal: FDA Accepts Supplement for ILUMYA (Tildrakizumab) by Sun Pharma